Ignyta Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
125
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.95B
Ignyta General Information
Description
Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.
Contact Information
Website
nexdx.comCorporate Office
- 4545 Towne Centre Court
- San Diego, CA 92121
- United States
Corporate Office
- 4545 Towne Centre Court
- San Diego, CA 92121
- United States
Ignyta Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 08-Feb-2018 | $1.95B | Completed | Generating Revenue | ||
| 9. Debt - General | 30-Jun-2016 | Completed | Generating Revenue | |||
| 8. 2PO | 20-May-2015 | Completed | Generating Revenue | |||
| 7. PIPE | 17-Mar-2015 | Completed | Generating Revenue | |||
| 6. PIPE | 14-Mar-2014 | Completed | Generating Revenue | |||
| 5. 2PO | 10-Mar-2014 | Completed | Generating Revenue | |||
| 4. Reverse Merger | 31-Oct-2013 | Completed | Generating Revenue | |||
| 3. Debt - General | 28-Feb-2013 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 01-Feb-2013 | $5.5M | $5.75M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 17-Oct-2011 | $250K | $250K | Completed | Product Development |
Ignyta Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Ignyta Comparisons
Industry
Financing
Details
Ignyta Competitors (1)
One of Ignyta’s competitors is Fore Biotherapeutics, a Venture Capital-Backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fore Biotherapeutics | Venture Capital-Backed | Philadelphia, PA |
Ignyta Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ignyta Patents
Ignyta Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4013404-A1 | Methods of treating cancer | Inactive | 14-Aug-2019 | ||
| US-20220257592-A1 | Methods of treating cancer | Inactive | 14-Aug-2019 | ||
| WO-2021030619-A1 | Methods of treating cancer | Inactive | 14-Aug-2019 | ||
| EP-3697390-A1 | Pharmaceutical compositions and dosage forms | Pending | 17-Oct-2017 | ||
| US-11007191-B2 | Pharmaceutical compositions and dosage forms | Active | 17-Oct-2017 | A61K9/167 |
Ignyta Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ignyta Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biobrit | Venture Capital | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| City Hill Ventures | Venture Capital | Minority | ||
| Colt Ventures | Family Office | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
Ignyta Investments & Acquisitions (3)
Ignyta’s most recent deal was a Corporate Asset Purchase with Teva Pharmaceutical (Four Oncology R&D Assets) for . The deal was made on 17-Mar-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Teva Pharmaceutical (Four Oncology R&D Assets) | 17-Mar-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Infinity Oil & Gas | 31-Oct-2013 | Merger/Acquisition | Energy Exploration | ||
| Actagene Oncology | 20-May-2013 | Merger/Acquisition | Pharmaceuticals |
Ignyta ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Ignyta FAQs
-
When was Ignyta founded?
Ignyta was founded in 2011.
-
Where is Ignyta headquartered?
Ignyta is headquartered in San Diego, CA.
-
What is the size of Ignyta?
Ignyta has 125 total employees.
-
What industry is Ignyta in?
Ignyta’s primary industry is Drug Discovery.
-
Is Ignyta a private or public company?
Ignyta is a Private company.
-
What is the current valuation of Ignyta?
The current valuation of Ignyta is .
-
What is Ignyta’s current revenue?
The current revenue for Ignyta is .
-
How much funding has Ignyta raised over time?
Ignyta has raised $90.4M.
-
Who are Ignyta’s investors?
Biobrit, Casdin Capital, City Hill Ventures, Colt Ventures, and Foresite Capital are 5 of 13 investors who have invested in Ignyta.
-
Who are Ignyta’s competitors?
Fore Biotherapeutics is a competitor of Ignyta.
-
When was Ignyta acquired?
Ignyta was acquired on 08-Feb-2018.
-
Who acquired Ignyta?
Ignyta was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
